January 21, 2026 12:45 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Nitin Nabin becomes BJP’s youngest president ahead of key assembly polls, PM Modi calls him ‘my boss’ | Viral video scandal rocks Karnataka Police: DGP Ramachandra Rao suspended | Jolt to ECI over SIR! SC allows BLAs at hearing, questions 'logical discrepancy'; TMC declares 'BJP's game over' | Will dal disrupt diplomacy? US lawmakers urge Trump to act on India’s 30% pulse tariff | 'Pakistan deserves Operation Sindoor 2.0', says Baloch leader over Trump’s Gaza board invitation to Islamabad | From Malda to the nation: PM Modi unveils India’s Vande Bharat sleeper | War zone Beldanga: Highway blocked, reporters attacked in migrant death protests | Can a Nobel Peace Prize be given away? Committee breaks silence after Machado hands over medal to Trump | Europe scrambles troops to Greenland as Trump’s takeover push triggers Arctic power showdown | Nobel drama: Venezuelan leader presents Peace Prize to Trump
Johnson Baby Powder
Image Credit: wikipedia.org

Maharashtra FDA cancels Johnson & Johnson baby powder licence

| @indiablooms | Sep 18, 2022, at 05:06 am

Mumbai: The Maharashtra FDA has cancelled the baby talcum powder manufacturing licence of Johnson & Johnson, Mulund, after the department found it "Not Of Standard Quality".

The FDA said that the licence was cancelled after samples of the Johnson’s Baby Powder collected from Nashik and Pune failed quality checks and ordered the company to recall all its stocks from the markets.

These samples were declared by the FDA as ‘Not Of Standard Quality’ after they failed to comply with IS5339:2009 (Second Revision Amendment No. 3) Specification for Skin Powder for infants in the test pH.

In a statement, the FDA said: “The product Johnsons Baby Powder is popularly used in newborn babies. The sample declared 'Not of Standard' in pH and the use of the product may affect the health of the skin of the newborn babies.”

The firm "didn't accept the report" and challenged it in court for sending it to the Central Drugs Laboratory, the FDA said, according to media reports.

(With UNI inputs)

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.